4.7 Article

Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions

Journal

FOOD AND CHEMICAL TOXICOLOGY
Volume 72, Issue -, Pages 312-321

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.fct.2014.04.029

Keywords

Mineral oil saturated hydrocarbons (MOSH); Fat tissue; Liver; Spleen; Mesenteric lymph nodes; Accumulation

Ask authors/readers for more resources

Of 37 subjects aged 25-91 y (mean 67 y), mineral oil hydrocarbons were measured in subcutaneous abdominal fat tissue, mesenteric lymph nodes (MLN), spleen, liver and lung, for some of them also in kidney, heart and brain. No mineral oil aromatic hydrocarbons (MOAN) were detected. The mean concentration of mineral oil saturated hydrocarbons (MUSH) in the mesenteric lymph nodes was 223 mg/kg, in liver 131 mg/kg, in fat tissue 130 mg/kg, in spleen 93 mg/kg and in lung 12 mg/kg. They were clearly lower in kidney, heart and brain. The maxima, found in MILN and spleen, were 1390 and 1400 mg/kg, respectively. For a quarter of the subjects a total amount of MOSH in the body above 5 g was calculated. The MOSH composition in the fat tissue and the MLN appeared virtually identical and varied little between the subjects. It was centered on the n-alkanes C-23-C-24, ranged from C-16 to C-35 and included hydrocarbons of plant origin. The MUSH in spleen and liver had almost the same composition for a given subject, but varied somewhat between subjects. They were centered between C-25 and C-27, ranged from C-18 to beyond C-45 and were without hydrocarbons of plant origin. Part of the MUSH seem to be strongly accumulated, resulting in far higher concentrations in human tissues related to exposure than observed in shorter term animal experiments. The composition of the accumulated MUSH does not support that Class I mineral oils, sometimes termed food grade, are less accumulated in the human body than Class H and III oils, which questions the present classification. (C) 2014 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin, Xavier Matias-Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio Gonzalez Martin, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A. Nout, Dearbhaile O'Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke Westermann, Pauline Wimberger, Nicoletta Colombo, Francois Planchamp, Carien L. Creutzberg

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Article Hematology

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Charles Herbaux, Christoph Kornauth, Stephanie Poulain, Stephen J. F. Chong, Mary C. Collins, Rebecca Valentin, Liam Hackett, Olivier Tournilhac, Francois Lemonnier, Jehan Dupuis, Adrien Daniel, Cecile Tomowiak, Kamel Laribi, Loic Renaud, Damien Roos-Weil, Cedric Rossi, Eric Van den Neste, Cecile Leyronnas, Fatiha Merabet, Jean Valere Malfuson, Mourad Tiab, Loic Ysebaert, Samuel Ng, Franck Morschhauser, Philipp B. Staber, Matthew S. Davids

Summary: Novel agent classes like JAK/STAT and T-cell receptor pathway inhibitors, as well as HDAC inhibitors, have shown preclinical activity in T-PLL. BH3 profiling revealed that primary T-PLL cells mainly depend on BCL-2 and MCL-1 proteins for survival. The combination therapy of venetoclax and ruxolitinib demonstrated significant efficacy in refractory T-PLL patients, especially in those with JAK3 mutations.

BLOOD (2021)

Letter Hematology

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Christoph Kornauth, Charles Herbaux, Bernd Boidol, Chantal Guillemette, Patrick Caron, Marius E. Mayerhoefer, Stephanie Poulain, Olivier Tournilhac, Tea Pemovska, Stephen J. F. Chong, Emiel van der Kouwe, Lukas Kazianka, Georg Hopfinger, Daniel Heintel, Roland Jaeger, Markus Raderer, Ulrich Jager, Ingrid Simonitsch-Klupp, Wolfgang R. Sperr, Stefan Kubicek, Matthew S. Davids, Philipp B. Staber

HAEMATOLOGICA (2021)

Article Oncology

Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis

Joanna Baum, Elena Ioana Braicu, Oliver Hunsicker, Ignace Vergote, Nicole Concin, Els Van Nieuwenhuysen, Aarne Feldheiser, Patriciu Achimas-Cadariu, Silvia Darb-Esfahani, Astrid Berger, Bogdan Fetica, Sven Mahner, Andrea Papadia, Linn Woelber, Maria Luisa Gasparri, Adriaan Vanderstichele, Pierluigi Benedetti Panici, Michael D. Mueller, Ilary Ruscito, Hannah Woopen, Jalid Sehouli

Summary: This study aimed to identify characteristics of long-term survivors with high-grade serous ovarian cancer and found that platinum sensitivity, recurrence, ascites, and BRCA1 gene mutation were significant factors affecting long-term survival. Intraoperatively, long-term survivors also had less tumor involvement of the upper abdomen.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Article Pathology

ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

Nicole Concin, Carien L. Creutzberg, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan A. Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio Gonzalez-Martin, Sigurd F. Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A. Nout, Dearbhaile E. O'Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina E. Sturdza, Alexandra Taylor, Anneke M. Westermann, Pauline Wimberger, Nicoletta Colombo, Francois Planchamp, Xavier Matias-Guiu

Summary: A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines. Given the large body of literature on the management of endometrial carcinoma published since 2014, the guidelines were updated by ESGO/ESTRO/ESP. The guidelines cover various aspects of endometrial carcinoma care and are evidence-based.

VIRCHOWS ARCHIV (2021)

Article Hematology

Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter

E. van der Kouwe, G. Heller, A. Czibere, J. A. Pulikkan, C. Agreiter, L. H. Castilla, R. Delwel, A. Di Ruscio, A. K. Ebralidze, M. Forte, F. Grebien, E. Heyes, L. Kazianka, J. Klinger, C. Kornauth, T. Le, K. Lind, I. A. M. Barbosa, T. Pemovska, A. Pichler, A-S Schmolke, C. M. Schweicker, H. Sill, W. R. Sperr, A. Spittler, S. Surapally, B. Q. Trinh, P. Valent, K. Vanura, R. S. Welner, J. Zuber, D. G. Tenen, P. B. Staber

Summary: The study reveals that downregulation of PU.1 in the blood system is an active process induced by an antisense promoter driven by RUNX transcription factors, resulting in myeloid differentiation blockade. Patients with CBF-AML show an elevated antisense/sense transcript ratio and promoter accessibility compared to normal karyotype AML or healthy CD34(+) cells. Additionally, competitive interaction between an enhancer and the proximal or antisense promoter acts as a binary switch for myeloid or T-cell development.

BLOOD (2021)

Article Oncology

Tissue distribution of epirubicin after severe extravasation in humans

Jakob Nedomansky, Werner Haslik, Ursula Pluschnig, Christoph Kornauth, Christine Deutschmann, Stefan Hacker, Guenther G. Steger, Rupert Bartsch, Robert M. Mader

Summary: Analyzing removed tissue from patients undergoing surgical intervention for extravasation of anthracyclines revealed individual variations in tissue sensitivity, with surgical intervention post-demarcation leading to healing within approximately 2 weeks. Despite high variability in tissue concentrations post-extravasation surgery, preventive measures remain crucial in preventing tissue necrosis.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Letter Oncology

Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?

Nicole Concin, Xavier Matias-Guiu, Carien L. Creutzberg

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Article Oncology

Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer

Charlotte Maene, Rawand Rokan Salihi, Els Van Nieuwenhuysen, Sileny N. Han, Nicole Concin, Ignace Vergote

Summary: This study found that the addition of bevacizumab to weekly paclitaxel and carboplatin in neoadjuvant treatment of cervical cancer stage IB-IIB resulted in a 100% radiological RECIST response and an optimal pathological response rate of 38%. Despite the established role of bevacizumab in combination with paclitaxel and carboplatin in recurrent cervical cancer, no superior effect on pathological response rate was observed in the neoadjuvant chemotherapy setting.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Article Oncology

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth, Tea Pemovska, Gregory Vladimer, Gunther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Martin Erl, Harald Esterbauer, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, Alexander Gaiger, Klaus Geissler, Hildegard T. Greinix, Wolfgang Gstoettner, Marcus Hacker, Bernd Lorenz Hartmann, Alexander W. Hauswirth, Tim Heinemann, Daniel Heintel, Mir Alireza Hoda, Georg Hopfinger, Ulrich Jaeger, Lukas Kazianka, Lukas Kenner, Barbara Kiesewetter, Nikolaus Krall, Gerhard Krajnik, Stefan Kubicek, Trang Le, Simone Lubowitzki, Marius E. Mayerhoefer, Elisabeth Menschel, Olaf Merkel, Katsuhiro Miura, Leonhard Muellauer, Peter Neumeister, Thomas Noesslinger, Katharina Ocko, Leopold Oehler, Michael Panny, Alexander Pichler, Edit Porpaczy, Gerald W. Prager, Markus Raderer, Robin Ristl, Reinhard Ruckser, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, Ilse Schwarzinger, Edgar Selzer, Christian Sillaber, Cathrin Skrabs, Wolfgang R. Sperr, Ismet Srndic, Renate Thalhammer, Peter Valent, Emiel van der Kouwe, Katrina Vanura, Stefan Vogt, Cora Waldstein, Dominik Wolf, Christoph C. Zielinski, Niklas Zojer, Ingrid Simonitsch-Klupp, Giulio Superti-Furga, Berend Snijder, Philipp B. Staber

Summary: Personalized medicine using functional assays can be clinically feasible and effective in providing treatment guidance for patients with aggressive hematologic cancers, resulting in enhanced progression-free survival and exceptional responses lasting longer than expected for some patients.

CANCER DISCOVERY (2022)

Article Oncology

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis

Daniela Berger, Karin Bauer, Christoph Kornauth, Susanne Gamperl, Gabriele Stefanzl, Dubravka Smiljkovic, Christian Sillaber, Peter Bettelheim, Paul Knoebl, Ana-Iris Schiefer, Georg Greiner, Renate Thalhammer, Gregor Hoermann, Ilse Schwarzinger, Philipp B. Staber, Wolfgang R. Sperr, Peter Valent

Summary: Secondary basophilic leukemia is a rare type of leukemia characterized by significant expansion of basophils during disease progression, with a generally poor prognosis. Monotherapy with azacitidine may not be sufficient to control the disease effectively, and combination therapy may offer potential for better outcomes. Future clinical studies are needed to determine the efficacy of drug combinations, such as venetoclax, in improving outcomes for these patients.

NEOPLASIA (2021)

Article Food Science & Technology

Monitoring and Occurrence of Heavy PAHs in Pomace Oil Supply Chain Using a Double-Step Solid-Phase Purification and HPLC-FLD Determination

Laura Barp, Sabrina Moret, Giorgia Purcaro

Summary: Polycyclic aromatic hydrocarbons (PAHs) are common environmental and processing contaminants generated by organic matter combustion processes. The contamination of PAHs in vegetable oils can come from various sources, including environmental pollution, oil processing, and migration from food contact materials. A purification method using solid-phase extraction (SPE) and high performance liquid chromatography-fluorometric detector (HPLC-FLD) analysis was developed to isolate PAHs from the complex matrix of edible oil. Evaluation of the pomace oil supply chain revealed an increase in PAH contamination with storage time and a significant contribution of the pomace drying process to the total PAH content.

FOODS (2022)

Article Biochemistry & Molecular Biology

Endogenous n-Alkanes in Vegetable Oils: Validation of a Rapid Offline SPE-GC-FID Method, Comparison with Online LC-GC-FID and Potential for Olive Oil Quality Control

Ana Srbinovska, Paolo Lucci, Chiara Conchione, Laura Barp, Sabrina Moret

Summary: The potential of endogenous n-alkane profiling for assessing EVOO adulteration has been studied by few authors. A rapid and solvent-sparing offline SPE-GC-FID method was optimized and validated for determining endogenous n-alkanes in vegetable oils. Promising indices were found to reveal the addition of SFO in EVOO and AVO in EVOO.

MOLECULES (2023)

Review Food Science & Technology

Pressurized Liquid Extraction: A Powerful Tool to Implement Extraction and Purification of Food Contaminants

Laura Barp, Ana Miklavcic Visnjevec, Sabrina Moret

Summary: Pressurized liquid extraction (PLE) is an advanced extraction technique aimed at saving time and reducing solvent in comparison to traditional extraction processes. It is commonly used for solid and semi-solid samples, employing solvent extraction at elevated temperatures and pressures. The use of specific pressure and temperature conditions changes the physicochemical properties of the extraction solvent, allowing deeper penetration into the matrix to be extracted. By combining extraction and clean-up steps, PLE becomes a versatile and selective technique. This review focuses on recent applications of PLE in the field of food contaminants.

FOODS (2023)

Article Multidisciplinary Sciences

Metabolic drug survey highlights cancer cell dependencies and vulnerabilities

Tea Pemovska, Johannes Bigenzahn, Ismet Srndic, Alexander Lercher, Andreas Bergthaler, Adrian Cesar-Razquin, Felix Kartnig, Christoph Kornauth, Peter Valent, Philipp B. Staber, Giulio Superti-Furga

Summary: Metabolic reprogramming plays a critical role in cancer development. The study demonstrates the use of a metabolic drug library to uncover metabolic vulnerabilities and gain functional insights into myeloid leukemia biology. High-throughput screening approaches are effective in identifying cancer-specific metabolic vulnerabilities and unraveling contextual biology.

NATURE COMMUNICATIONS (2021)

No Data Available